Literature DB >> 12186946

Reduced IRS-2 and GLUT4 expression in PPARgamma2-induced adipocytes derived from C/EBPbeta and C/EBPdelta-deficient mouse embryonic fibroblasts.

Hiroyasu Yamamoto1, Shogo Kurebayashi, Takahisa Hirose, Haruhiko Kouhara, Soji Kasayama.   

Abstract

In adipose tissue, the ability of cells to respond to insulin and to express genes such as those encoding fatty-acid-binding protein (422/aP2), lipoprotein lipase (LPL), adipsin and glucose transporter 4 (GLUT4) is acquired during their differentiation into mature adipocytes. It has been recognized that peroxisome proliferator-activated receptor gamma (PPARgamma) and CCAAT/enhancer-binding proteins (C/EBPs) play critical roles in adipocyte differentiation. However, it remained uncertain whether PPARgamma or which C/EBP is involved in the acquisition of these characteristics. We introduced PPARgamma2 into C/EBPbeta/delta-double deficient mouse embryonic fibroblasts (MEFs), followed by stimulation with its ligands, in order to define the roles of C/EBPbeta and C/EBPdelta in phenotypic acquisition during adipocyte differentiation. This procedure resulted in differentiation of these MEFs into mature adipocytes morphologically similar to wild-type MEFs. However, the adipocytes derived from the C/EBPbeta/delta-deficient MEFs showed lower expression of GLUT4 and adipsin mRNA than those derived from wild-type MEFs, although aP2 and LPL mRNA levels were similar in both types. The C/EBPbeta/delta-deficient adipocytes also expressed lower amounts of insulin receptor substrate 2 (IRS-2) than the adipocytes derived from wild-type MEFs, whereas the amounts of insulin receptor and IRS-1 were similar. Finally, insulin-responsive 2-deoxyglucose uptake was lower in the C/EBPbeta/delta-deficient cells. It could thus be demonstrated that C/EBPbeta and C/EBPdelta are involved in the acquisition of IRS-2 and GLUT4 expression as well as in insulin-sensitive glucose uptake during adipocyte differentiation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12186946     DOI: 10.1242/jcs.00044

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  6 in total

1.  Protein arginine methyltransferase 5 (Prmt5) promotes gene expression of peroxisome proliferator-activated receptor γ2 (PPARγ2) and its target genes during adipogenesis.

Authors:  Scott E LeBlanc; Silvana Konda; Qiong Wu; Yu-Jie Hu; Christine M Oslowski; Saïd Sif; Anthony N Imbalzano
Journal:  Mol Endocrinol       Date:  2012-02-23

2.  Suppression of the C/EBP family of transcription factors in adipose tissue causes lipodystrophy.

Authors:  Raghunath Chatterjee; Paramita Bhattacharya; Oksana Gavrilova; Kimberly Glass; Jaideep Moitra; Max Myakishev; Stephanie Pack; William Jou; Lionel Feigenbaum; Michael Eckhaus; Charles Vinson
Journal:  J Mol Endocrinol       Date:  2011-04-15       Impact factor: 5.098

3.  C/EBP transcription factors regulate SREBP1c gene expression during adipogenesis.

Authors:  Victoria A Payne; Wo-Shing Au; Christopher E Lowe; Shaikh M Rahman; Jacob E Friedman; Stephen O'Rahilly; Justin J Rochford
Journal:  Biochem J       Date:  2009-12-14       Impact factor: 3.857

Review 4.  CCAAT/enhancer binding protein β in relation to ER stress, inflammation, and metabolic disturbances.

Authors:  Sophie E van der Krieken; Herman E Popeijus; Ronald P Mensink; Jogchum Plat
Journal:  Biomed Res Int       Date:  2015-01-28       Impact factor: 3.411

5.  Sequential regulation of diacylglycerol acyltransferase 2 expression by CAAT/enhancer-binding protein beta (C/EBPbeta) and C/EBPalpha during adipogenesis.

Authors:  Victoria A Payne; Wo-Shing Au; Sarah L Gray; Edoardo Dalla Nora; Shaikh M Rahman; Rebecca Sanders; Dirk Hadaschik; Jacob E Friedman; Stephen O'rahilly; Justin J Rochford
Journal:  J Biol Chem       Date:  2007-05-14       Impact factor: 5.157

6.  Genome-wide methylated DNA immunoprecipitation analysis of patients with polycystic ovary syndrome.

Authors:  Hao-Ran Shen; Li-Hua Qiu; Zhi-Qing Zhang; Yuan-Yuan Qin; Cong Cao; Wen Di
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.